Success for Glaxo’s 3D mark for purple asthma inhaler

Success for Glaxo’s 3D mark for purple asthma inhaler
European Union

Glaxo has prevailed on appeal in these long-running invalidity proceedings, with the General Court annulling a EUIPO decision invalidating Glaxo’s 3D mark for the shape of an inhaler.

Unlock unlimited access to all WTR content